Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Atopic Dermatitis Competitive Landscape Report 2026: Comprehensive Insights About 100+ Companies and 110+ Drugs

globenewswire.com
INCY Incyte is mentioned as a company with a marketed therapy, OPZELURA, for Atopic Dermatitis. The article provides a neutral overview of the competitive landscape and does not offer specific positive or negative commentary on Incyte's performance or prospects. MRK Merck Sharp & Dohme LLC is listed with an early-stage (Phase I) product, MK-6194, for Atopic Dermatitis. The article is a report overview, and this mention is factual without expressing positive or negative sentiment towards Merck.

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.

The report reveals extensive insights concerning over 100 companies and more than 110 drugs within the Atopic Dermatitis (AD) landscape. This analysis examines therapeutic assessments by product type, development stage, route of administration, and molecule category, as well as specifics on inactive pipeline products. The report's coverage is global, providing a comprehensive understanding of AD.

This report offers a thorough commercial overview, focusing on collaborations, licensing, and acquisitions. It provides a comparative assessment of companies based on therapy type, development stage, and technology. Key questions address current treatments versus emerging therapies, highlighting novel approaches in the pipeline.

Market leaders across the US, Europe, and Japan present topical solutions, including emollients and corticosteroids, and advanced systemic treatments like Dupixent. Highlighting pipeline innovations, the report details significant clinical trials and partnerships targeting novel therapeutic developments.

Report Highlights:

Key Company Profiles:

Key Players & Products:

Key Topics Covered:

Introduction

Executive Summary

Atopic dermatitis: Overview

Atopic dermatitis - Analytical Perspective: In-depth Commercial Assessment

Competitive Landscape

Therapeutic Assessment

Atopic dermatitis: Company and Product Profiles (Marketed Therapies)

Incyte

OPZELURA

Atopic dermatitis: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Phase III)

Cara Therapeutics

Difelikefalin

Mid Stage Products (Phase II)

Bayer

Zabedosertib

Early Stage Products (Phase I)

Merck Sharp & Dohme LLC

MK-6194

Preclinical and Discovery Stage Products

Company Name

Product Name

Inactive Products

Atopic dermatitis- Unmet needs

Atopic dermatitis - Market drivers and barriers

Appendix

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/3paeyl

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.